Show simple item record

dc.contributor.authorOteo-Iglesias, Jesús 
dc.contributor.authorLázaro, Edurne
dc.contributor.authorAbajo Iglesias, Francisco J de 
dc.contributor.authorBaquero, Fernando
dc.contributor.authorCampos, Jose 
dc.date.accessioned2020-05-05T08:59:06Z
dc.date.available2020-05-05T08:59:06Z
dc.date.issued2005-04
dc.identifier.citationEmerg Infect Dis. 2005 Apr;11(4):546-53.es_ES
dc.identifier.issn1080-6040es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9885
dc.description.abstractSurveillance System. A network of 32 Spanish hospitals, serving approximately 9.6 million persons, submitted antimicrobial-susceptibility data on 7,098 invasive Escherichia coli species (2001-2003). Resistance to ampicillin, cotrimoxazole, ciprofloxacin, gentamicin, and tobramycin was found at rates of 59.9%, 32.6%, 19.3%, 6.8%, and 5.3%, respectively. Resistance to multiple drugs increased from 13.8% in 2001 to 20.6% in 2003 (p <0.0001). Antimicrobial consumption data were obtained from the Spanish National Health System. In spite of decreased cephalosporin and beta-lactam use, overall extended-spectrum beta-lactamase production increased from 1.6% (2001) to 4.1% (2003) (p <0.0001), mainly due to the rising prevalence of cefotaximases. Resistance to ciprofloxacin significantly increased, mostly in community-onset infections, which coincided with a rise in community quinolone use. Cotrimoxazole resistance remained stable at approximately 30%, even though its use was dramatically reduced.es_ES
dc.description.sponsorshipEARSS is funded by the European Commission, DG Sanco (Agreement SI2.123794). This work was supported by research grants MPY 1012/04 (Instituto de Salud Carlos III, Ministry of Health) and SBVI1284/02-13 (Dirección General de Salud Pública, Ministry of Health, Spain).es_ES
dc.language.isoenges_ES
dc.publisherCenters for Disease Control and Preventiones_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnti-Bacterial Agents es_ES
dc.subject.meshDrug Resistance, Multiple, Bacterial es_ES
dc.subject.meshEscherichia coli es_ES
dc.subject.meshEscherichia coli Infections es_ES
dc.subject.meshHumans es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshSpain es_ES
dc.subject.meshTime Factors es_ES
dc.subject.meshDrug Resistance, Bacterial es_ES
dc.titleAntimicrobial-resistant invasive Escherichia coli, Spaines_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID15829192es_ES
dc.format.volume11es_ES
dc.format.number4es_ES
dc.format.page546-53es_ES
dc.identifier.doi10.3201/eid1104.040699es_ES
dc.contributor.funderEuropean Commission
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.contributor.funderMinisterio de Sanidad y Consumo (España)
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3201/eid1104.040699es_ES
dc.identifier.journalEmerging infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SI2.123794es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/MPY 1012/04es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SBVI1284/02-13es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional